CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TargED Biopharmaceuticals is developing TGD001, a novel drug designed to treat various blood clots associated with thrombosis. This innovative therapy targets both von Willebrand Factor and fibrin, offering a comprehensive solution for thrombotic conditions with improved safety and efficacy.
TargED Biopharmaceuticals B.V., a spin-off from UMC Utrecht, is developing TGD001, an innovative first-in-class drug designed to treat all types of blood clots associated with thrombosis, a leading global cause of death that currently has limited effective treatments.
TGD001 has shown superior results in preclinical studies, demonstrating high precision, safety, and efficacy, and TargED has raised over €45 million to fund its clinical trials, moving toward market readiness.Unlike existing therap…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
